NASDAQ: ACETAdicet Bio Inc Stock
$1.88-0.22 (-10.48%)
Updated Apr 24, 2024
ACET Price
$1.88
Fair Value Price
$3.22
Market Cap
$154.04M
52 Week Low
$1.10
52 Week High
$7.50
P/E
-0.57x
P/B
0.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$142.66M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
-$94M
Beta
1.06
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ACET Overview
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACET scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACET ($1.88) is undervalued by 41.85% relative to our estimate of its Fair Value price of $3.22 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACET ($1.88) is significantly undervalued by 41.85% relative to our estimate of its Fair Value price of $3.22 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ACET is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACET due diligence checks available for Premium users.
Be the first to know about important ACET news, forecast changes, insider trades & much more!
ACET News
Valuation
ACET fair value
Fair Value of ACET stock based on Discounted Cash Flow (DCF)
Price
$1.88
Fair Value
$3.22
Undervalued by
41.70%
ACET ($1.88) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACET ($1.88) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACET is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACET price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.57x
Industry
15.69x
Market
41.27x
ACET price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.91x
Industry
5.86x
ACET is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACET's financial health
Profit margin
Revenue
$0.0
Net Income
-$29.5M
Profit Margin
0%
ACET's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$207.3M
Liabilities
$37.1M
Debt to equity
0.22
ACET's short-term assets ($162.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACET's short-term assets ($162.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACET's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACET's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.5M
Investing
-$136.0k
Financing
$76.0k
ACET's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACET vs Biotech Stocks
Adicet Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.